AUPH News and Press, Aurinia Pharmaceuticals Inc From 10/13/23

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that data from 14 studies of LUPKYNIS ® (voclosporin) wi...

2023-09-27 11:02:40 ET Summary Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for diseases with high unmet medical need. The company has been the subject of frequent takeover rumors and continues to gain impressive sales ...

2023-09-27 01:48:57 ET Summary Aurinia Pharmaceuticals reports Q2 2023 revenue of $41.5M, up 47% YoY, driven by Lupkynis sales; however, SG&A expenses still exceed revenue. Strong liquidity with $415.9M current assets, but insider selling and 9.93% short interest raise investo...

2023-09-21 06:54:43 ET More on Aurinia Seeking Alpha’s Quant Rating on Aurinia Pharma Historical earnings data for Aurinia Pharma Aurinia: Strategic Alternatives Could Go Either Way For Stakeholders Aurinia spikes on Q2 earnings beat, guidance raise ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, “MKT Capital”...

2023-09-18 14:18:23 ET Aurinia Pharmaceuticals (NASDAQ: AUPH) , a company focused on developing treatments for autoimmune diseases, saw its share price fall by more than 5% in early trading on Monday. The stock has recovered some of its losses since hitting this intraday low, but it...

Dr. Karen Smith and Jeffrey A. Bailey joined Aurinia’s Board of Directors August 18, 2023 Dr. Daniel G. Billen appointed Chair of the Board of Directors Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that...

2023-08-03 12:32:02 ET Aurinia Pharmaceuticals Inc. (AUPH) Q2 2023 Earnings Conference Call August 3, 2023, 8:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Con...

2023-08-03 06:40:52 ET More on Aurinia Pharma Aurinia: Strategic Alternatives Could Go Either Way For Stakeholders Aurinia Pharmaceuticals: Still In The Game With Lupkynis Sales Aurinia: Despite Milder Shareholder Vote, A Bid To Sell Is Still Not Over Aurinia...

2023-08-03 06:02:12 ET Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.08 beats by $0.11 . Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M . Increases 2023 revenue guidance range to $150 - $160 million from net product sales of LUPKYNIS ...